Plasma biomarkers are useful tools in the diagnosis and prognosis of heart failure (HF). In
the last decade, numerous studies have aimed to identify novel HF biomarkers that would …

Objective, noninvasive, clinical assessment of patients with heart failure can be made using
biomarker measurements, including natriuretic peptides, cardiac troponins, soluble …

Since natriuretic peptides were successfully integrated into the clinical practice of heart
failure (HF), the possibility of using new biomarkers to advance the management of affected …

Despite the enhanced knowledge of the pathophysiology of heart failure (HF), it still remains
a serious syndrome with substantial morbidity, mortality, and frequent hospitalizations …

BACKGROUND Until recently, biomarker testing in heart failure (HF) syndromes has been
viewed as an elective supplement to diagnostic evaluation of patients suspected to suffer …

Although substantial improvements have been made in majority of cardiac disorders, heart
failure (HF) remains a major health problem, with both increasing incidence and prevalence …

ST2 and galectin-3 are emerging biomarkers in the field of heart failure and have been
extensively studied, and that whether they provide additional prognostic value on top of the …

Heart failure (HF) has proven to be a major burden on the health system. The continuing
prevalence of the condition and its rising associated costs and care, has amplified the need …

Background and Purpose: Natriuretic peptides have led the way as a diagnostic and
prognostic tool for the diagnosis and management of heart failure (HF). More recent …

While there have been significant recent advances in the medical management of chronic
HF (including the use of beta-blockers, angiotensin-converting enzyme inhibitors …